Calithera Biosciences, Inc. (NASDAQ:CALA) has received an average recommendation of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $14.40.
Several equities research analysts recently commented on CALA shares. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “strong-buy” rating and set a $21.00 price objective on the stock in a research report on Tuesday, July 11th. William Blair initiated coverage on shares of Calithera Biosciences in a research report on Thursday, October 5th. They issued an “outperform” rating on the stock. Finally, BidaskClub lowered shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a report on Friday, July 28th.
Shares of Calithera Biosciences (CALA) traded down $0.70 during midday trading on Friday, hitting $17.20. 871,398 shares of the company’s stock traded hands, compared to its average volume of 446,269. Calithera Biosciences has a 52 week low of $2.50 and a 52 week high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. The business had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $6.02 million. sell-side analysts predict that Calithera Biosciences will post -0.77 earnings per share for the current fiscal year.
In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the company’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $15.64, for a total value of $9,008,640.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 16.30% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of CALA. Nationwide Fund Advisors acquired a new position in shares of Calithera Biosciences during the 1st quarter valued at about $131,000. Bank of New York Mellon Corp increased its position in Calithera Biosciences by 17.5% during the 1st quarter. Bank of New York Mellon Corp now owns 32,688 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 4,863 shares in the last quarter. FMR LLC increased its position in Calithera Biosciences by 278.2% during the 1st quarter. FMR LLC now owns 1,462,190 shares of the biotechnology company’s stock worth $16,888,000 after purchasing an additional 1,075,592 shares in the last quarter. Vanguard Group Inc. increased its position in Calithera Biosciences by 99.8% during the 1st quarter. Vanguard Group Inc. now owns 925,015 shares of the biotechnology company’s stock worth $10,684,000 after purchasing an additional 462,137 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Calithera Biosciences by 61.6% during the 1st quarter. Geode Capital Management LLC now owns 107,169 shares of the biotechnology company’s stock worth $1,236,000 after purchasing an additional 40,841 shares in the last quarter. 71.22% of the stock is owned by institutional investors.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
What are top analysts saying about Calithera Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Calithera Biosciences Inc. and related companies.